Group B Streptococcus

Details for Australian Patent Application No. 2005319174 (hide)

Owner Novartis Vaccines and Diagnostics Inc.

Inventors Tettelin, Herve; Masignani, Vega

Agent FB Rice

Pub. Number AU-A-2005319174

PCT Pub. Number WO2006/069200

Priority 60/638,943 22.12.04 US; 60/640,438 30.12.04 US

Filing date 21 December 2005

Wipo publication date 29 June 2006

International Classifications

C07K 14/315 (2006.01) Peptides having more than 20 amino acids

C07K 16/12 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from bacteria

C12N 15/31 (2006.01) Mutation or genetic engineering - Genes encoding microbial proteins, e.g. enterotoxins

Event Publications

21 June 2007 PCT application entered the National Phase

  PCT publication WO2006/069200 Priority application(s): WO2006/069200

3 April 2008 Alteration of Name

  The name of the applicant has been altered to Novartis Vaccines and Diagnostics Inc.; J. Craig Venter Institute, Inc. Amendments

19 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005319176-Compositions comprising anti-IGF-1 receptor antibodies and methods for obtaining said antibodies

2005319167-Imidazo[4,5-C]pyridine compound and method of antiviral treatment